Welcome to our dedicated page for Renew Energy Global Plc SEC filings (Ticker: RNWWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding renewable-energy disclosures is no small task. Capacity maps, turbine yield tables and carbon-credit notes sprawl across hundreds of pages in ReNew Energy Global Plc’s reports. If you’re searching for ReNew Energy Global Plc insider trading Form 4 transactions or the latest ReNew Energy Global Plc quarterly earnings report 10-Q filing, the sheer volume can slow decision-making.
Stock Titan solves that problem. Our AI engine reads every line the moment it hits EDGAR, then delivers plain-English answers to questions like “understanding ReNew Energy Global Plc SEC documents with AI.” Whether you need a snapshot of wind-farm output from the ReNew Energy Global Plc annual report 10-K simplified or a real-time alert on ReNew Energy Global Plc Form 4 insider transactions real-time, our platform surfaces the data within seconds. Key filings and what you’ll learn are laid out below:
- 10-K & 10-Q – capacity additions, tariff rates and segment revenue with ReNew Energy Global Plc earnings report filing analysis.
- 8-K – turbines damaged or new power-purchase agreements; see ReNew Energy Global Plc 8-K material events explained.
- Form 4 – monitor ReNew Energy Global Plc executive stock transactions Form 4 before market shifts.
- DEF 14A – dive into ReNew Energy Global Plc proxy statement executive compensation without wading through legal jargon.
Every filing is accompanied by AI-powered summaries, cross-linked exhibits and capacity trend charts, so you grasp how new wind, solar and hydro projects reshape cash flow—without parsing accounting footnotes. Real-time notifications, exportable data tables and historical archives make Stock Titan the fastest route to ReNew Energy Global Plc SEC filings explained simply.
Celcuity Inc. (Nasdaq: CELC) filed a Form 8-K on 30 June 2025 to furnish a press release containing preliminary clinical data for its PI3K/mTOR inhibitor gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).
In the Phase 1 portion of the study, 38 patients were randomised to receive 600 mg darolutamide twice daily with either 120 mg (Arm 1) or 180 mg (Arm 2) gedatolisib administered once weekly for three weeks on/one week off. Data cut-off was 30 May 2025. Key efficacy and safety results for the pooled arms were:
- 66 % six-month radiographic progression-free survival (rPFS)
- 0 treatment-related discontinuations and no dose reductions
- No Grade 3 hyperglycaemia reported
- Grade 2-3 stomatitis observed in 4 patients (10.5 %)
The company intends to enroll up to six patients in each of three additional Phase 1 dosing arms, followed by up to 40 patients in Phase 1b to establish the recommended Phase 2 dose (RP2D). A Phase 2 expansion will bring the total treated at RP2D to approximately 30 subjects. All participants will continue to receive standard darolutamide.
Celcuity emphasised that the Item 7.01 information is being furnished, not filed, and included customary forward-looking-statement language regarding trial timelines, regulatory prospects, market opportunity, and capital requirements.
FAQ
What is the current stock price of Renew Energy Global Plc (RNWWW)?
What is the core business of ReNew Energy Global Plc?
Which energy segments does the company operate in?
How does ReNew Energy Global Plc generate revenue?
What differentiates ReNew Energy Global Plc in the renewable energy market?
How is technology integrated into the company’s operations?
What role does wind power play in its portfolio?
In what ways does the company address sustainability?
How does ReNew Energy Global Plc navigate the competitive landscape?
